Head of the FDA is requesting a federal investigation into the approval process for Biogen's Alzheimer's disease drug Aduhelm. The investigation will involve an independent evaluation of the interaction between Biogen and the FDA to determine whether the interaction conflicted with FDA policies and procedures.